QuantaMatrix Inc. (KOSDAQ: 317690)

Market Cap	148.18B
Revenue (ttm)	3.60B
Net Income (ttm)	-17.94B
Shares Out	16.54M
EPS (ttm)	-1,085.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	771,905
Open	8,750.00
Previous Close	8,770.00
Day's Range	8,680.00 - 9,310.00
52-Week Range	3,360.00 - 23,700.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About QuantaMatrix

QuantaMatrix Inc. operates as an in-vitro diagnostics company in South Korea. Its products include dRAST, a direct and rapid antimicrobial susceptibility test for treating sepsis that provides MIC-based phenotypic antimicrobial susceptibility testing direct from positive blood culture; QDST, a rapid phenotypic drug susceptibility testing system for tuberculosis; QPLEX Alz plus assay, an early diagnosis kit for Alzheimer's disease; and Quanti9 and QuantiGal, a prognostic prediction kit for cardiovascular diseases. The company was founded in 2010...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 317690

Financial Performance

In 2023, QuantaMatrix's revenue was 3.12 billion, an increase of 142.47% compared to the previous year's 1.29 billion. Losses were -21.56 billion, 12.1% more than in 2022.